Oral rimegepant for migraine prevention

Research output: Contribution to journal › Debate/Note/Editorial

Standard

Oral rimegepant for migraine prevention. / Edvinsson, Lars.

In: The Lancet, Vol. 397, No. 10268, 2021, p. 4-5.

Research output: Contribution to journal › Debate/Note/Editorial

Harvard

Edvinsson, L 2021, 'Oral rimegepant for migraine prevention', The Lancet, vol. 397, no. 10268, pp. 4-5. https://doi.org/10.1016/S0140-6736(20)32624-6

APA

Edvinsson, L. (2021). Oral rimegepant for migraine prevention. The Lancet, 397(10268), 4-5. https://doi.org/10.1016/S0140-6736(20)32624-6

CBE

Edvinsson L. 2021. Oral rimegepant for migraine prevention. The Lancet. 397(10268):4-5. https://doi.org/10.1016/S0140-6736(20)32624-6

MLA

Edvinsson, Lars. "Oral rimegepant for migraine prevention". The Lancet. 2021, 397(10268). 4-5. https://doi.org/10.1016/S0140-6736(20)32624-6

Vancouver

Edvinsson L. Oral rimegepant for migraine prevention. The Lancet. 2021;397(10268):4-5. https://doi.org/10.1016/S0140-6736(20)32624-6

Author

Edvinsson, Lars. / Oral rimegepant for migraine prevention. In: The Lancet. 2021 ; Vol. 397, No. 10268. pp. 4-5.

RIS

TY - JOUR

T1 - Oral rimegepant for migraine prevention

AU - Edvinsson, Lars

PY - 2021

Y1 - 2021

U2 - 10.1016/S0140-6736(20)32624-6

DO - 10.1016/S0140-6736(20)32624-6

M3 - Debate/Note/Editorial

C2 - 33338436

AN - SCOPUS:85098652613

VL - 397

SP - 4

EP - 5

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10268

ER -